4.5 Article

Impaired bed mobility in prediagnostic and de novo Parkinson's disease

Journal

PARKINSONISM & RELATED DISORDERS
Volume 98, Issue -, Pages 47-52

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.parkreldis.2022.04.007

Keywords

Parkinson's disease; Impaired bed mobility; Turning in bed; Prodromal Parkinson's disease; Motor complications

Funding

  1. Michael J. Fox Foundation for Parkinson's Research
  2. Abbvie
  3. Acure
  4. Allergan
  5. Amathus
  6. Avid
  7. Biogen
  8. Bial Biotech
  9. Bio-legend
  10. Bristol-Myers Squibb
  11. Calico
  12. Celgene
  13. Covance
  14. Dacapo brain-science
  15. Jenali
  16. 4D Pharma plc
  17. GE Healthcare
  18. Edmond J. Safra phil-anthropic foundation
  19. Genentech
  20. GlaxoSmithKline
  21. Golub Capital
  22. Handl Therapeutics
  23. Insitro
  24. Janssen Neuroscience
  25. Lilly
  26. Lundbeck
  27. Merck
  28. Meso Scale Discovery
  29. Neurocine
  30. Pfizer
  31. Piramal
  32. Prevail
  33. Roche
  34. Sanofi Genzyme
  35. Servier
  36. Takeda
  37. Teva
  38. UCB
  39. Verily and Voyager therapeutics

Ask authors/readers for more resources

This study suggests that impaired bed mobility can be a clinical symptom for screening prodromal PD and predicting motor complications in early PD.
Background: Wearable technology research suggests that nocturnal movements are disturbed in early Parkinson's disease (PD). In this study, we investigate if patients also already experience impaired bed mobility before PD diagnosis. Furthermore, we explore its association with motor and nonmotor features and its value for phenoconversion and disease progression prediction. Methods: PPMI data were downloaded for de novo PD subjects, subjects at-risk for developing a synucleinopathy (with isolated REM sleep behavior disorder, hyposmia or a pathogenic genetic variant) and controls. Impaired bed mobility was assessed with the MDS-UPDRS part 2 item 9. A frequency analysis was performed. Multivariable logistic regression analyses were used to investigate the association with other PD variables. Cox proportional-hazards models were used to test if difficulties with turning in bed could predict phenoconversion. Linear mixed models were used to evaluate if difficulties with turning in bed could predict disease progression. Results: Of the at-risk subjects, 9.2-12.5% experienced difficulties with turning in bed vs. 25.0% of de novo PD subjects and 2.5% of controls. Impaired turning ability was associated with MDS-UPDRS motorscore (axial signs in the at-risk group, bradykinesia in the de novo PD group) and SCOPA-AUT score (gastrointestinal symptoms). In addition, difficulties with turning in bed were a significant predictor for phenoconversion in the at-risk group and for development of motor complications in the de novo PD group. Conclusion: Our findings suggest that difficulties with turning in bed can be helpful as clinical symptom for a prodromal PD screening and for motor complication prediction in early PD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available